Comparison of four immunohistochemical tests and FISH for measuring Her2 expression in gastric carcinomas-Reference-Cited by-同舟云学术

Comparison of four immunohistochemical tests and FISH for measuring Her2 expression in gastric carcinomas

Published:2012-04 Issue:3 Volume:44 Page:216-220
ISSN:0031-3025
Container-title:Pathology
language:en
Short-container-title:Pathology

Author:

Cho Eun Yoon,Srivastava Amitabh,Park Kyeongmee,Kim Jiyun,Lee Min Hyeong,Do Ingu,Lee Jeeyun,Kim Kyoung-Mee,Sohn Tae Sung,Kang Won Ki,Kim Sung

Publisher

Elsevier BV

Subject

Pathology and Forensic Medicine

Reference42 articles.

1. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world;Kamangar;J Clin Oncol,2006

2. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2- positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial;Bang;Lancet,2010

3. Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC);Cutsem;J Clin Oncol,2009

4. Cardiac toxicity in breast cancer survivors: review of potential cardiac problems;Bird;Clin Cancer Res,2008

5. Correlation between immunohisto- chemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres;Dowsett;J Pathol,2003

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. What Therapeutic Biomarkers in Gastro-Esophageal Junction and Gastric Cancer Should a Pathologist Know About?;Surgical Pathology Clinics;2023-12

2. p70S6K/Akt dual inhibitor DIACC3010 is efficacious in preclinical models of gastric cancer alone and in combination with trastuzumab;Scientific Reports;2023-09-25

3. Novel Biomarkers of Gastric Cancer: Current Research and Future Perspectives;Journal of Clinical Medicine;2023-07-12

4. Supporting Biomarker-Driven Therapies in Oncology: A Genomic Testing Cost Calculator;The Oncologist;2023-03-24

5. Deviating HER2 test results in gastric cancer: analysis from the prospective multicenter VARIANZ study;Journal of Cancer Research and Clinical Oncology;2022-08-27